Articles tagged with Prostate Cancer
A new study by USC/Norris Cancer Center scientists raises questions about the potential use of finasteride to prevent prostate cancer. Finasteride, commonly used to treat benign prostate disease, may not be effective as a chemopreventive agent against prostate cancer in men with high PSA levels.
A new molecule, Bin1, has been identified by Wistar scientists as a potential indicator of malignant prostate cancer. Bin1 interacts with and limits the malignant potential of Myc, a protein found frequently in prostate cancers.
Researchers found that anti-androgen drugs can trigger the protein that makes prostate and cancerous cells grow, leading to a possible explanation for why hormone therapy loses effectiveness after one or two years. The study suggests that more research is needed to confirm the results.
A new study by Johns Hopkins researchers found that older men have more extensive prostate disease even if their PSA levels are the same as younger men. The study suggests that age should be an additional guide in deciding whether to do further testing for non-palpable prostate cancer.
A new test measuring free PSA can accurately identify men at risk of prostate cancer, allowing for targeted biopsies and reducing unnecessary procedures. The test aims to cut the cost of prostate screening dramatically while sparing men from potential complications like infection and bleeding.
A new version of the PSA test detects 95% of prostate cancers and helps distinguish between cancer and benign conditions. The study reduces unnecessary biopsies and provides personalized risk assessments for men with borderline results.
Scientists at Duke University discovered a genetic switch that governs prostate cancer progression. The switch controls the production of FGF-R2 receptors, which can lead to
The FDA panel unanimously approved a new test for detecting prostate cancer, which catches almost all cancers and reduces unnecessary biopsies. The free PSA test, measuring unbound PSA in the blood, identifies patients who could benefit from surgery or treatments, reducing cancer-free men's biopsies by 20%.
Researchers found that high 'free' testosterone levels in adulthood and a small shoulder span may be related to hormone levels at various stages of development, suggesting a link between these factors and prostate cancer risk. Further study is needed to confirm these findings.
A new study of over 1,000 prostate cancer patients found that those who underwent surgery had remarkably good outcomes, with few reporting dissatisfaction or problems with urinary or sexual function. Despite fears about complications, most men felt healthier and satisfied with their treatment after surgery.
The newly revised nomograms combine clinical stage, Gleason score, and PSA level information to identify men who can be cured by surgery alone. The use of these nomograms should improve our ability to predict surgical curability and help patients make informed treatment decisions.
A new study by Washington University School of Medicine researchers found that a surprising 22 percent of men with prostate cancer had PSA levels between 2.6 and 4, highlighting the need for yearly PSA tests for men over 50. The study suggests that doctors may be missing cancers in this range due to outdated guidelines.
A new study by Johns Hopkins Medicine recommends reducing the annual frequency of prostate-specific antigen (PSA) testing for men between 50 and 70 years old, as most don't need frequent tests to detect curable cancers. The guidelines suggest PSA testing every two years is sufficient to identify most men with curable prostate cancer.
Researchers at the University of Pittsburgh Cancer Institute have found that vitamin D significantly reduces prostate cancer growth in rats. Tumors in treated rats were 88% smaller than those in control rats, and lung metastases were also reduced.
Researchers found that a lower free-to-total PSA ratio may indicate aggressive prostate cancer. The study suggests this ratio can help doctors distinguish between serious and non-serious cases, leading to better treatment decisions.
A new study predicts prostate cancer up to six years earlier than current methods by analyzing the ratio of free to total prostate-specific antigen (PSA) in a man's blood. The research, published in 1996, showed that men with high total PSA levels may have prostate cancer or benign prostatic hypertrophy.
Scientists have identified a major gene, HPC-1, that predisposes men to prostate cancer, located on chromosome 1. The gene is believed to contribute to at least a third of familial prostate cancer cases.
Researchers at the University of Chicago Medical Center have found that testosterone can shrink experimental human prostate tumors that no longer depend on the hormone. This suggests a potential new approach for treating advanced prostate cancer.
A multi-institutional study found that surgery is effective for localized prostate cancer, with tumor grade being the best predictor of long-term survival. Ten years after surgery, men with grade 1 tumors had a 6% mortality rate, while those with grade 2 and 3 tumors had 20% and 23% mortality rates, respectively.
Stanford researchers are working on a new PSA test that can distinguish between cancerous and non-cancerous prostate enlargement. By analyzing the PSA protein extracted from enlarged prostates, they aim to eliminate unnecessary biopsies. The team's approach has shown promising results, reducing false positives by up to 86%.